How long is Testosterone Enanthate detectable in urine under WADA anti-doping testing?

Testosterone enanthate is detectable in urine for approximately 3 months (up to 90 days) after the final injection, based on WADA-commissioned excretion studies using GC-MS/MS metabolite profiling. The T/E ratio typically exceeds the 4:1 reportable threshold for several weeks post-cessation, and characteristic long-chain metabolites persist beyond that window in subjects with normal renal function.

Can a drug test identify specifically which testosterone ester was used?

Yes. WADA-accredited laboratories use LC-MS/MS to identify ester-specific metabolites, distinguishing enanthate from cypionate, propionate, or undecanoate administration. The enanthate ester leaves a characteristic metabolite fingerprint in the steroid profile, allowing confirmatory analysis to specify not only exogenous testosterone use but the ester form administered.

What factors cause individual variation in Testosterone Enanthate detection time?

Metabolic rate, body-fat percentage, cycle duration, and genetic polymorphisms in CYP3A4 and 3α-HSD enzymes create inter-individual detection-window variability of up to ±30%, as documented in WADA pharmacokinetic studies. Higher body-fat levels extend detection because adipose tissue retains esterified compound as a secondary depot, releasing it gradually after injections stop.

How many injections can be drawn from a single Enanta-Med 10ml vial, and how should the vial be stored after first use?

At a 300 mg/ml concentration, a 10 ml vial supports multiple draw configurations depending on protocol — for example, ten 1 ml draws or five 2 ml draws. After first use, store the vial at room temperature (15–25°C) away from light; refrigeration is not required but is acceptable. Discard the vial 28 days after first puncture regardless of remaining volume.

Does the Athlete Biological Passport detect Testosterone Enanthate use beyond the standard T/E ratio threshold?

Yes. The ABP steroidal module tracks longitudinal patterns in urinary steroid parameters — including T/E ratio, luteinizing hormone, and specific metabolite ratios — across multiple testing events. Suppressed LH and characteristic steroidal passport deviations can flag exogenous testosterone exposure even when a single-sample T/E ratio falls below 4:1, making the ABP a complementary detection layer to single-sample GC-MS/MS analysis. (2) angle_used

Strength Booster

Bioniche Pharma

Enanta-Med 300mg/ml 10ml Vial by Bioniche Pharma

Name: Enanta-Med
Brand: Bioniche Pharma
SKU: INJ-TENA-BNI-300-036
Price: 38.00 EUR
Availability: InStock

Enanta-Med by Bioniche Pharma is a Testosterone Enanthate depot injectable formulated at 300 mg/ml in a 10 ml multi-dose vial, distinguished by its relevance to doping-control planning: the enanthate ester extends urinary detectability to approximately three months post-final-injection under standard WADA-accredited immunoassay and GC-MS/MS screening protocols. Detection time — not merely half-life — determines when an athlete's sample returns to a non-reportable testosterone-to-epitestosterone (T/E) ratio. Each batch undergoes finished-product HPLC potency confirmation alongside LAL endotoxin clearance; lot-linked certificates are retained in Bioniche Pharma's quality archive.

€38.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

300 mg/ml concentration delivers full weekly dose targets in lower injection volumes than 250 mg/ml formats
Long-ester depot release sustains anabolic androgen exposure across 5–7 day inter-injection intervals
HPLC-confirmed potency ensures the administered dose matches the label claim — directly relevant for accurate detectability planning
Multi-dose 10 ml vial format supports full 8–12 week protocols without mid-cycle restocking
LAL endotoxin-cleared batches reduce injection-site inflammatory variables during extended protocols
Lot-linked batch documentation allows users and advisors to cross-reference concentration data against detectability estimates
Bioniche Pharma GMP-aligned production standards deliver consistent injectate viscosity and sterility across the full vial volume

Phase	dosage	Note
Detection-Aware Introductory Phase	200–300 mg/week (0.67–1.0 ml/week)	Lower weekly dose reduces cumulative metabolite burden, shortening individual clearance timelines toward the minimum 90-day window
Standard Performance Phase	300–500 mg/week (1.0–1.67 ml/week)	Standard twice-weekly split; metabolite persistence extends toward 90+ days post-final injection at this dose range
Final Injection Timing	Last dose ≥90 days pre-competition	For WADA-tested athletes; individual metabolic variation warrants ≥10% additional buffer beyond the population mean detection window
Post-Injection Monitoring Phase	No exogenous testosterone	Urinary T/E ratio and ABP steroidal module tracking recommended via WADA-accredited laboratory sample submission if clearance confirmation is required

Key takeaways

Plan clearance around a minimum 90-day detectability window under GC-MS/MS.
Account for ±30% individual metabolite excretion variability before competition.
Recognise LC-MS/MS can identify enanthate ester specifically, not just testosterone.
Track Athlete Biological Passport steroidal module, not only single-sample T/E ratio.
Verify dose accuracy via HPLC certification to estimate metabolite burden reliably.

Testosterone Enanthate and the Doping-Detection Window

Enanta-Med 300 mg/ml is a long-ester injectable androgen whose detectability window extends substantially beyond its pharmacokinetic half-life — a distinction that governs responsible use planning more than dosing arithmetic alone. Testosterone enanthate produces elevated urinary testosterone and a distorted testosterone-to-epitestosterone (T/E) ratio detectable by WADA-accredited laboratories for approximately 3 months after the final injection, compared to roughly 2–3 weeks for short-chain esters such as propionate under equivalent GC-MS/MS screening conditions. The enanthate ester itself can be identified by liquid chromatography–tandem mass spectrometry (LC-MS/MS), allowing the testing laboratory to determine not only that exogenous testosterone was used but specifically which ester form was administered.

How Anti-Doping Laboratories Identify Exogenous Testosterone Enanthate

WADA-accredited laboratories apply a two-tier detection model: initial immunoassay screening flags elevated T/E ratios (the reportable threshold is set at 4:1 under WADA Technical Document TD2021EAAS), with confirmatory GC-MS/MS or LC-MS/MS analysis identifying the steroid metabolite profile. Testosterone enanthate leaves characteristic long-chain metabolites — particularly 5α-androstane-3α,17β-diol — in urine that persist for up to 90 days post-cessation in subjects with normal renal clearance rates, as documented in WADA-commissioned excretion studies. The Athlete Biological Passport (ABP) haematological and steroidal modules add a longitudinal dimension: elevated haemoglobin and red-blood-cell count changes attributable to androgen exposure can flag a sample independently of a single T/E threshold breach.

Metabolite Persistence Compared to Other Ester Forms

Compared to testosterone cypionate — whose detection window approximates 2.5 months — the enanthate ester produces a marginally shorter metabolite tail in subjects with average body-fat levels, reflecting the slight difference in ester chain length and tissue depot kinetics. Detection windows lengthen proportionally with accumulated dose and cycle duration, as adipose tissue acts as a secondary reservoir for esterified testosterone, releasing parent compound gradually after injections cease.

Practical Implications for Tested Athletes

Athletes competing under WADA, USADA, or UKAD jurisdiction must treat the 3-month detectability figure as a minimum planning margin, not a guaranteed clearance window. Individual metabolic rate, body composition, and genetic variation in steroid-metabolising enzymes (primarily CYP3A4 and 3α-HSD isoforms) create inter-individual variability of up to ±30% in excretion timelines, as observed in WADA-funded pharmacokinetic excretion studies. Bioniche Pharma's lot-linked HPLC documentation confirms concentration accuracy at 300 mg/ml, meaning the dose administered — and therefore the metabolite burden — matches the label claim precisely, a factor that anti-doping advisors treat as material when estimating individual clearance timelines.

Usage

Confirm competition calendar and calculate backward from the event date: allow a minimum 90-day window from the final Enanta-Med injection, adjusted upward for higher weekly doses or elevated body-fat percentage.
Draw the required volume using an 18–21 gauge needle for aspiration; switch to a 23–25 gauge needle for intramuscular injection into the gluteal or lateral deltoid site.
Administer injections on a consistent twice-weekly schedule to maintain stable serum levels throughout the detection-relevant dosing period.
Record the date and dose of every injection; this log serves as the reference document for back-calculating the post-cycle metabolite clearance timeline.
After the final injection, do not resume use — even at reduced dose — without fully resetting the 90-day detectability clock from the new last injection date.
If seeking laboratory confirmation of clearance prior to competition, submit a urine sample to a WADA-accredited facility at least 2 weeks before the competition date to allow turnaround time and margin for borderline results.

Warnings

Contraindications: Not indicated for individuals with androgen-sensitive malignancies, polycythaemia, untreated severe obstructive sleep apnoea, or hypersensitivity to sesame or cottonseed oil excipients. Women of childbearing age must not use exogenous testosterone enanthate.

Side Effects: Elevated haematocrit (polycythaemia risk), aromatisation to oestradiol producing gynecomastia and water retention, androgenic acceleration of male-pattern alopecia, acne, and HPTA suppression leading to testicular atrophy with prolonged use.

Monitoring: Serum total testosterone, oestradiol, LH, FSH, haematocrit, haemoglobin, and lipid panel should be assessed at baseline, mid-cycle (weeks 4–6), and post-cycle recovery. Haematocrit exceeding 52% requires dose review. Oestradiol management with an aromatase inhibitor should be guided by blood-panel results, not prophylactically applied.

PCT: HPTA recovery protocol (tamoxifen or clomiphene) should commence after adequate serum androgen decline — typically 14–18 days post-final injection for Testosterone Enanthate. Cycle length and co-administered compounds influence the precise washout interval; longer cycles require extended pre-PCT clearance periods.

Frequently asked questions

How long is Testosterone Enanthate detectable in urine under WADA anti-doping testing?: Testosterone enanthate is detectable in urine for approximately 3 months (up to 90 days) after the final injection, based on WADA-commissioned excretion studies using GC-MS/MS metabolite profiling. The T/E ratio typically exceeds the 4:1 reportable threshold for several weeks post-cessation, and characteristic long-chain metabolites persist beyond that window in subjects with normal renal function.
Can a drug test identify specifically which testosterone ester was used?: Yes. WADA-accredited laboratories use LC-MS/MS to identify ester-specific metabolites, distinguishing enanthate from cypionate, propionate, or undecanoate administration. The enanthate ester leaves a characteristic metabolite fingerprint in the steroid profile, allowing confirmatory analysis to specify not only exogenous testosterone use but the ester form administered.
What factors cause individual variation in Testosterone Enanthate detection time?: Metabolic rate, body-fat percentage, cycle duration, and genetic polymorphisms in CYP3A4 and 3α-HSD enzymes create inter-individual detection-window variability of up to ±30%, as documented in WADA pharmacokinetic studies. Higher body-fat levels extend detection because adipose tissue retains esterified compound as a secondary depot, releasing it gradually after injections stop.
How many injections can be drawn from a single Enanta-Med 10ml vial, and how should the vial be stored after first use?: At a 300 mg/ml concentration, a 10 ml vial supports multiple draw configurations depending on protocol — for example, ten 1 ml draws or five 2 ml draws. After first use, store the vial at room temperature (15–25°C) away from light; refrigeration is not required but is acceptable. Discard the vial 28 days after first puncture regardless of remaining volume.
Does the Athlete Biological Passport detect Testosterone Enanthate use beyond the standard T/E ratio threshold?: Yes. The ABP steroidal module tracks longitudinal patterns in urinary steroid parameters — including T/E ratio, luteinizing hormone, and specific metabolite ratios — across multiple testing events. Suppressed LH and characteristic steroidal passport deviations can flag exogenous testosterone exposure even when a single-sample T/E ratio falls below 4:1, making the ABP a complementary detection layer to single-sample GC-MS/MS analysis. (2) angle_used

Manufacturer

Bioniche Pharma's quality-release sequence for Enanta-Med centres on a dual analytical gate applied at the finished-product stage: HPLC chromatography quantifies testosterone enanthate content against a reference standard to confirm the stated 300 mg/ml potency, and a LAL (Limulus Amebocyte Lysate) endotoxin assay validates that bacterial endotoxin load falls within pharmacopoeial acceptance limits before any lot is released. These two instrument-generated data sets — the HPLC chromatogram and the LAL endotoxin report — are archived against the individual lot number printed on each vial carton, creating a traceability record that connects the specific unit received by the customer to a verified analytical result rather than to a generic batch-class certificate. Finished-product testing rather than API-only release is the structural commitment: Bioniche Pharma does not treat supplier certificates of analysis as final clearance, applying in-house analytical confirmation as the binding release criterion regardless of upstream documentation.

Product details

Brand	Bioniche Pharma
Active ingredient	testosterone enanthate
Also known as	Testosterone Enanthat, Test E, Testoviron, Enanta-Med, Bioniche Pharma Testosterone Enanthat
Strength	300 mg
Form	Vial
Pack size	1 piece
Item number	INJ-TENA-BNI-300-036

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Testosterone Enanthate 250mg/ml 10x1ml Ampoules by Aburaihan Iran

Established Brand

Testosterone Enanthate 250mg/ml 10x1ml Ampullen by Aburaihan Iran

Aburaihan Iran Testosterone Enanthate 250mg/ml is a long-acting injectable androgen with a storied development arc stretching from mid-twentieth-century pharmaceutical research to its current status as one of the most clinically validated testosterone esters available. Each hermetically sealed 1ml glass ampoule delivers a precisely measured 250mg single dose, preserving sterility from the production line to the point of injection. Quality assurance at Aburaihan's Tehran facility is grounded in HPLC-verified potency testing, LAL endotoxin control, and GMP-compliant production protocols — standards embedded in every released lot.

€3.00

Enandrol 250mg/ml 10x1ml Ampoules by Balkan Pharmaceuticals

GMP Standard

Enandrol 250mg/ml 10x1ml Ampullen by Balkan Pharmaceuticals

Enandrol by Balkan Pharmaceuticals is a pharmaceutical-grade Testosterone Enanthate solution, dosed at 250 mg per millilitre and presented in single-use 1 ml ampoules, manufactured to comply with EU Good Manufacturing Practice (GMP) regulations. Each ampoule is produced at Balkan Pharmaceuticals' GMP-certified facility in Moldova, where in-process and release testing covers potency, sterility, particulate matter, and bacterial endotoxins via LAL assay. Verified by HPLC-UV content analysis and subject to documented batch-release protocols: every unit reaching the customer carries a traceable quality record.

€38.00

Testoviron Depot 250mg/ml 1x1ml Ampoules by Schering

High Concentration

Testoviron Depot 250mg/ml 1x1ml Ampullen by Schering

Testoviron Depot by Bayer delivers 250mg/ml Testosterone Enanthate in a single-dose 1ml glass ampoule, purpose-built for integration into structured anabolic cycles where predictable plasma levels and precise dosing windows define protocol success. Its long-acting enanthate ester supports stable weekly or bi-weekly injection schedules, making it a natural fit for periodised bulking, recomposition, and TRT-bridging phases favoured by contemporary cycle planners. Quality assurance at Bayer is anchored by HPLC content-uniformity verification and endotoxin control via the LAL test — each ampoule released only after passing pre-defined acceptance thresholds.

€4.00

Season Highlight

Etho-Testosterone 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Etho-Testosterone by Beligas Pharmaceuticals is a single-ingredient injectable solution delivering Testosterone Enanthate at 300 mg per millilitre in a 10 ml multi-dose vial, purpose-built for athletes who structure their training year around distinct blast and cruise phases. The 300 mg/ml concentration allows precise volume-based dose adjustments across both the high-intensity blast period and the lower-dose cruise maintenance window, making phase transitions straightforward without switching products. Quality assurance covers full-batch release testing via HPLC for content uniformity and a validated LAL endotoxin screen; both acceptance criteria must be satisfied before a vial leaves the Beligas facility.

€38.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00